The effect of nebivolol on atherogenesis in apoE-knockout mice.
Nebivolol is a novel beta1-blocker with a nitric oxide (NO)--potentiating, vasodilatory effect that is unique among beta-blockers. It was already shown that nebivolol ameliorates atherosclerosis in cholesterol-fed rabbits. We, therefore, wanted to investigate whether this is the case in the fine experimental model of atherosclerosis: apolipoprotein E (apoE)-knockout mice. Nebivolol attenuated atherogenesis, measured both by "en face" method (9.23+/-1.8% vs. 14.6+/-2.1%) and "cross-section" method (63125+/-8455 microm(2) vs. 91416+/-8357 m(2)). This is the first report showing the effect of nebivolol on atherogenesis in gene-targeted mice.
Kus
K
K
Jagiellonian University Medical College, Cracow, Poland.
Gajda
M
M
Pyka-Fosciak
G
G
Toton-Zuranska
J
J
Pawlowska
M
M
Suski
M
M
Niepsuj
A
A
Nowak
B
B
Wolkow
P
P
Olszanecki
R
R
Jawien
J
J
Korbut
R
R
D058671:Adrenergic beta-1 Receptor Antagonists; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000818:Animals; D001011:Aorta / Q000187:drug effects / Q000473:pathology; D001057:Apolipoproteins E / Q000172:deficiency / Q000235:genetics; D050197:Atherosclerosis / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D001578:Benzopyrans / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D051379:Mice; D018345:Mice, Knockout; D000068577:Nebivolol; D012720:Severity of Illness Index; D014280:Triglycerides / Q000097:blood; D014665:Vasodilator Agents / Q000627:therapeutic use*
D058671:Adrenergic beta-1 Receptor Antagonists; D000319:Adrenergic beta-Antagonists; D001057:Apolipoproteins E; D001578:Benzopyrans; D004983:Ethanolamines; D014280:Triglycerides; D014665:Vasodilator Agents; D000068577:Nebivolol; D002784:Cholesterol